DM
MCID: DRM010
MIFTS: 62

Dermatomyositis (DM) malady

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Skin diseases, Muscle diseases

Aliases & Classifications for Dermatomyositis

Aliases & Descriptions for Dermatomyositis:

Name: Dermatomyositis 12 50 51 56 52 42 14 69
Amyopathic Dermatomyositis 12 50 69
Adult Dermatomyositis 50 56
Polymyositis with Skin Involvement 12
Dermatopolymyositis, Unspecified 12
Dermatomyositis Sine Myositis 50
Adult Type Dermatomyositis 69
Dermatopolymyositis 12
Adm 50
Dm 56

Characteristics:

Orphanet epidemiological data:

56
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:10223
ICD10 33 M33 M33.9 M33.90
ICD9CM 35 710.3
MeSH 42 D003882
NCIt 47 C26744
Orphanet 56 ORPHA221
ICD10 via Orphanet 34 M33.1 M33.0
MESH via Orphanet 43 D003882
UMLS via Orphanet 70 C0011633
UMLS 69 C0011633

Summaries for Dermatomyositis

NINDS : 51 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to tuberculosis and rheumatoid arthritis, and has symptoms including pruritus, arthralgia and fatigue. An important gene associated with Dermatomyositis is CHD4 (Chromodomain Helicase DNA Binding Protein 4), and among its related pathways/superpathways are Allograft rejection and Fluid shear stress and atherosclerosis. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; gottron's papules and heliotrope eyelids. pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. while patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. fatigue is reported in at least 50% of patients. some cases have been associated with internal malignancy and/or interstitial lung disease. treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (iv) immunoglobulin. last updated: 1/10/2013

Disease Ontology : 12 A myositis that results_in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

Wikipedia : 71 Dermatomyositis (DM) is a rare connective-tissue disease related to polymyositis (PM) that is... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
id Related Disease Score Top Affiliating Genes
1 tuberculosis 29.7 IL17A PIK3C2A TNF
2 rheumatoid arthritis 29.3 ICAM1 IL17A IL1A TNF VCAM1
3 childhood type dermatomyositis 12.3
4 adult dermatomyositis 12.0
5 neonatal dermatomyositis 11.9
6 c9 deficiency 11.6
7 polymyositis 11.4
8 myositis 11.4
9 myotonic dystrophy 1 11.3
10 maturity-onset diabetes of the young 11.2
11 diabetes insipidus 11.2
12 idiopathic inflammatory myopathy 11.1
13 antisynthetase syndrome 11.1
14 cryptogenic organizing pneumonia 11.1
15 epidermolysis bullosa simplex, dowling-meara type 11.0
16 diaphyseal medullary stenosis with malignant fibrous histiocytoma 10.7
17 lung disease 10.4
18 interstitial lung disease 10.4
19 calcinosis 10.3
20 infiltrating ureter transitional cell carcinoma 10.2 CHKB PIK3C2A TNF
21 right ventricle hypoplasia 10.1 ICAM1 TNF VCAM1
22 pyelonephritis 10.1 ICAM1 PIK3C2A TNF
23 erb-duchenne and dejerine-klumpke palsies 10.1 ICAM1 TNF VCAM1
24 hypotrichosis 4 10.1 ICAM1 IL1A TNF
25 pneumonia 10.1
26 persistent mullerian duct syndrome 10.1 ICAM1 TNF VCAM1
27 lupus erythematosus 10.1
28 dentinogenesis imperfecta 10.1 ICAM1 PIK3C2A VCAM1
29 asbestosis 10.1 PIK3C2A TNF VCAM1
30 periodontosis 10.1 ICAM1 IL1A TNF
31 balkan nephropathy 10.1 ICAM1 IL17A TNF
32 pemphigus vulgaris, familial 10.1 ICAM1 TNF VCAM1
33 lymphedema 10.1 ICAM1 IL1A VCAM1
34 xanthogranulomatous cholecystitis 10.1 ICAM1 IL17A TNF
35 orofacial granulomatosis 10.1 ICAM1 IL1A VCAM1
36 retinal ischemia 10.0 ICAM1 SFTPD TNF
37 synovium cancer 10.0 ICAM1 TNF VCAM1
38 optic nerve hypoplasia 10.0 ICAM1 IL17A TNF
39 skin conditions 10.0 IL1A SFTPD TNF
40 aplasia cutis autosomal recessive 10.0 HARS KARS TARS
41 pigmentation disease 10.0 ICAM1 TNF VCAM1
42 neonatal jaundice 10.0 ICAM1 IL17A TNF
43 inclusion body myositis 10.0
44 arthritis 10.0
45 myopathy 10.0
46 systemic lupus erythematosus 10.0
47 anaplastic large cell lymphoma 10.0 ICAM1 IL1A TNF
48 melanoma 10.0
49 nervous system cancer 10.0 IFIH1 IL1A SFTPD TNF
50 microscopic breast papilloma 10.0 ICAM1 PIK3C2A TNF

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

56 32 (show top 50) (show all 52)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 56 32 Frequent (79-30%) HP:0000989
2 arthralgia 56 32 Frequent (79-30%) HP:0002829
3 fatigue 56 32 Frequent (79-30%) HP:0012378
4 myalgia 56 32 Very frequent (99-80%) HP:0003326
5 fever 56 32 Occasional (29-5%) HP:0001945
6 dry skin 56 32 Frequent (79-30%) HP:0000958
7 periorbital edema 56 32 Very frequent (99-80%) HP:0100539
8 muscular hypotonia 56 32 Frequent (79-30%) HP:0001252
9 dysphonia 56 32 Occasional (29-5%) HP:0001618
10 respiratory insufficiency 56 32 Frequent (79-30%) HP:0002093
11 arthritis 56 32 Frequent (79-30%) HP:0001369
12 recurrent respiratory infections 56 32 Frequent (79-30%) HP:0002205
13 feeding difficulties in infancy 56 32 Occasional (29-5%) HP:0008872
14 pulmonary fibrosis 56 32 Frequent (79-30%) HP:0002206
15 acrocyanosis 56 32 Frequent (79-30%) HP:0001063
16 abnormality of the nail 56 32 Frequent (79-30%) HP:0001597
17 emg abnormality 56 32 Very frequent (99-80%) HP:0003457
18 myocardial infarction 56 32 Occasional (29-5%) HP:0001658
19 lung adenocarcinoma 56 32 Occasional (29-5%) HP:0030078
20 weight loss 56 32 Frequent (79-30%) HP:0001824
21 autoimmunity 56 32 Very frequent (99-80%) HP:0002960
22 skin ulcer 56 32 Frequent (79-30%) HP:0200042
23 abnormal hair quantity 56 32 Frequent (79-30%) HP:0011362
24 abnormality of the eyelid 56 32 Very frequent (99-80%) HP:0000492
25 aplasia/hypoplasia of the skin 56 32 Occasional (29-5%) HP:0008065
26 erythema 56 32 Very frequent (99-80%) HP:0010783
27 pericarditis 56 32 Occasional (29-5%) HP:0001701
28 myocarditis 56 32 Occasional (29-5%) HP:0012819
29 cellulitis 56 32 Occasional (29-5%) HP:0100658
30 abnormality of eosinophils 56 32 Occasional (29-5%) HP:0001879
31 vasculitis 56 32 Occasional (29-5%) HP:0002633
32 lymphoma 56 32 Occasional (29-5%) HP:0002665
33 breast carcinoma 56 32 Occasional (29-5%) HP:0003002
34 cutaneous photosensitivity 56 32 Occasional (29-5%) HP:0000992
35 papule 56 32 Frequent (79-30%) HP:0200034
36 chondrocalcinosis 56 32 Frequent (79-30%) HP:0000934
37 gangrene 56 32 Occasional (29-5%) HP:0100758
38 proximal muscle weakness 56 32 Very frequent (99-80%) HP:0003701
39 diffuse reticular or finely nodular infiltrations 56 32 Frequent (79-30%) HP:0002207
40 inflammatory myopathy 56 32 Very frequent (99-80%) HP:0009071
41 sinus tachycardia 56 32 Occasional (29-5%) HP:0011703
42 gastrointestinal stroma tumor 56 32 Occasional (29-5%) HP:0100723
43 edema 56 Very frequent (99-80%)
44 arrhythmia 56 Occasional (29-5%)
45 pulmonary hypertension 56 Occasional (29-5%)
46 neoplasm 56 Occasional (29-5%)
47 teleangiectasia of the skin 56 Occasional (29-5%)
48 abnormality of the voice 56 Occasional (29-5%)
49 interstitial pulmonary disease 56 Frequent (79-30%)
50 pulmonary arterial hypertension 32 HP:0002092

UMLS symptoms related to Dermatomyositis:


exanthema, pruritus

MGI Mouse Phenotypes related to Dermatomyositis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CHD4 ICAM1 IFIH1 IL17A IL1A PIK3C2A
2 immune system MP:0005387 9.7 ICAM1 IFIH1 IL17A IL1A PIK3C2A S100A9
3 mortality/aging MP:0010768 9.47 AARS CHD4 GARS ICAM1 IFIH1 IL17A

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Investigational Phase 4 53179-13-8 40632
3 Vaccines Phase 4
4 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
5 Hormones Phase 4,Phase 3,Phase 2,Phase 1
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Adrenocorticotropic Hormone Phase 4,Phase 2
12 beta-endorphin Phase 4,Phase 2
13 Melanocyte-Stimulating Hormones Phase 4,Phase 2
14 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
17
Cyclosporine Approved, Investigational, Vet_approved Phase 3 79217-60-0, 59865-13-3 5284373 6435893
18
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
19
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
22
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
23
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
24
Benzocaine Approved Phase 2, Phase 3 1994-09-7, 94-09-7 2337
25
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
26
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
27
Infliximab Approved Phase 2, Phase 3 170277-31-3
28
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
29
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
30
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
31
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
32
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
35 tannic acid Approved, Nutraceutical Phase 2, Phase 3
36 Antiemetics Phase 3,Phase 2
37 Antifungal Agents Phase 3
38 Anti-Infective Agents Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 3,Phase 2
40 Antimetabolites, Antineoplastic Phase 3,Phase 2
41 Antineoplastic Agents, Hormonal Phase 3,Phase 2
42 Autonomic Agents Phase 3,Phase 2
43 Calcineurin Inhibitors Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 glucocorticoids Phase 3,Phase 2,Phase 1
48 Methylprednisolone acetate Phase 3,Phase 2
49 Methylprednisolone Hemisuccinate Phase 3,Phase 2
50 Neuroprotective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
id Name Status NCT ID Phase
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4
4 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4
5 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4
6 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3
7 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3
10 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3
11 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3
12 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3
13 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3
14 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3
15 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3
16 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3
17 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3
18 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3
19 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2
20 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2
21 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2
22 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2
23 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2
24 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2
25 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2
26 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
27 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2
28 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2
29 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2
30 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2
31 Trial of IMO-8400 in Adult Patients With Dermatomyositis Recruiting NCT02612857 Phase 2
32 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Recruiting NCT02466243 Phase 2
33 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
34 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2
35 A Study In Adults With Moderate To Severe Dermatomyositis Not yet recruiting NCT03181893 Phase 2
36 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2
37 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2
38 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2
39 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
40 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1
41 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
42 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
43 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1
44 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1
45 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Recruiting NCT02780674 Phase 1
46 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320
47 A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy Unknown status NCT00971828
48 Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy Completed NCT02880527
49 Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis Completed NCT01813617
50 Hand Function in Patients With Poly- or Dermatomyositis Completed NCT00866125

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

MalaCards organs/tissues related to Dermatomyositis:

39
Skin, Lung, Heart, Breast, T Cells, Bone, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomyositis:

18
Muscle Or

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 1278)
id Title Authors Year
1
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
2
Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. ( 28089977 )
2017
3
Race and income affects outcomes in juvenile dermatomyositis. ( 28434566 )
2017
4
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. ( 27803134 )
2017
5
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. ( 28073708 )
2017
6
Environmental factors associated with disease flare in juvenile and adult dermatomyositis. ( 28444299 )
2017
7
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. ( 28514969 )
2017
8
Recurrence of juvenile dermatomyositis 8A years after remission. ( 28050594 )
2017
9
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
10
Image Gallery: Palmoplantar hyperkeratosis in dermatomyositis with anti-PM/Scl antibodies. ( 28504398 )
2017
11
Paraneoplastic Dermatomyositis. ( 28457044 )
2017
12
Dermatomyositis Patients with Anti-Nuclear Matrix Protein-2 Autoantibodies Have More Edema, More Severe Muscle Disease, and Increased Malignancy Risk. ( 28085235 )
2017
13
Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis. ( 28443580 )
2017
14
Juvenile dermatomyositis: a tertiary center experience. ( 28058540 )
2017
15
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
16
Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. ( 27995057 )
2017
17
MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis. ( 28480196 )
2017
18
Unsuspected Active Ulcerative Colitis in a Patient With Dermatomyositis: A Rare Association Detected on (18)F-FDG PET/CT During the Search for an Occult Malignancy. ( 28533643 )
2017
19
A case of dermatomyositis with underlying unusual malignancy. ( 28513483 )
2017
20
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
21
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. ( 28077146 )
2017
22
Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. ( 28460448 )
2017
23
Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. ( 28490218 )
2017
24
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. ( 28488124 )
2017
25
Successful resection of liver metastasis detected by exacerbation of skin symptom in a patient with dermatomyositis accompanied by rectal cancer: a case report and literature review. ( 28054279 )
2017
26
Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia. ( 28045754 )
2017
27
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. ( 28448730 )
2017
28
Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. ( 28451794 )
2017
29
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
30
Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. ( 28487565 )
2017
31
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. ( 27761751 )
2016
32
Analysis of sexual function of patients with dermatomyositis and polymyositis through self-administered questionnaires: a cross-sectional study. ( 27865559 )
2016
33
Methotrexate-Associated Classic Hodgkin Lymphoma in a Patient With Dermatomyositis. ( 27556248 )
2016
34
Isaacs' syndrome in a patient with dermatomyositis: case report and review of the literature. ( 27135791 )
2016
35
Dermatomyositis as a symptom of primary lung cancer: A case report and review of the literature. ( 27123126 )
2016
36
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. ( 27588444 )
2016
37
Association of vitamin D receptor gene BsmI B/b and FokI F/f polymorphisms with adult dermatomyositis and systemic lupus erythematosus. ( 26972080 )
2016
38
Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. ( 26891180 )
2016
39
Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. ( 27605457 )
2016
40
Pulmonary embolism induced by methotrexate in a dermatomyositis patient. ( 27659404 )
2016
41
Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. ( 26872621 )
2016
42
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. ( 27908312 )
2016
43
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27155307 )
2016
44
Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review. ( 27167896 )
2016
45
Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate? ( 27312550 )
2016
46
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. ( 27623619 )
2016
47
Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years. ( 27607893 )
2016
48
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. ( 27606477 )
2016
49
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. ( 27615411 )
2016
50
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. ( 28004387 )
2016

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

Pathways related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 HARS ICAM1 IL17A IL1A TNF
2 11.88 ICAM1 IL1A TNF VCAM1
3 11.69 ICAM1 TNF VCAM1
4 11.66 ICAM1 IL1A TNF VCAM1
5 11.58 ICAM1 IL17A IL1A TNF
6 11.53 ICAM1 TNF VCAM1
7 11.49 CHD3 CHD4 TNF
8 11.41 ICAM1 IL17A IL1A TNF VCAM1
9 11.34 ICAM1 IL1A TNF
10
Show member pathways
11.34 AARS GARS HARS IARS KARS TARS
11 11.32 ICAM1 TNF VCAM1
12
Show member pathways
11.26 ICAM1 IL1A TNF VCAM1
13 11.12 ICAM1 TNF VCAM1
14 10.64 ICAM1 TNF VCAM1

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.46 ICAM1 IL17A TNF VCAM1
2 NuRD complex GO:0016581 9.32 CHD3 CHD4
3 extracellular space GO:0005615 9.23 ICAM1 IL17A IL1A KARS S100A9 SFTPD
4 aminoacyl-tRNA synthetase multienzyme complex GO:0017101 8.96 IARS KARS
5 cytoplasm GO:0005737 10.1 AARS CHD3 CHD4 GARS HARS IARS

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.77 ICAM1 IFIH1 KARS MORC3 VCAM1
2 regulation of translational fidelity GO:0006450 9.49 AARS IARS
3 response to copper ion GO:0046688 9.48 ICAM1 IL1A
4 leukocyte tethering or rolling GO:0050901 9.46 TNF VCAM1
5 tRNA aminoacylation GO:0043039 9.43 AARS TARS
6 translation GO:0006412 9.43 AARS GARS HARS IARS KARS TARS
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.4 IL17A KARS
8 membrane to membrane docking GO:0022614 9.32 ICAM1 VCAM1
9 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.26 ICAM1 TNF
10 diadenosine tetraphosphate biosynthetic process GO:0015966 9.16 GARS KARS
11 tRNA aminoacylation for protein translation GO:0006418 9.1 AARS GARS HARS IARS KARS TARS

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.9 AARS CHD3 CHD4 CHKB GARS HARS
2 integrin binding GO:0005178 9.61 ICAM1 UTRN VCAM1
3 tRNA binding GO:0000049 9.43 AARS IARS KARS
4 ligase activity GO:0016874 9.43 AARS GARS HARS IARS KARS TARS
5 hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides GO:0016818 9.4 CHD3 CHD4
6 aminoacyl-tRNA editing activity GO:0002161 9.37 AARS IARS
7 ligase activity, forming aminoacyl-tRNA and related compounds GO:0016876 9.32 AARS TARS
8 aminoacyl-tRNA ligase activity GO:0004812 9.1 AARS GARS HARS IARS KARS TARS

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....